Tags : Certain Types

Biosimilars Biotech Regulatory

Amgen and Allergan’s Mvasi (bevacizumab, biosimilar) + Combination Therapy Receives

Shots: The approval is based on P-III study results assessing Mvasi vs bevacizumab in patients with non-squamous NSCLC The study demonstrated in biosimilarity of Mvasi with bevacizumab in terms of efficacy, safety and immunogenicity Mvasi (bevacizumab, biosimilar) is a IgG1 mAb, binds to VEGF and inhibits the interaction of VEGF with its receptors, VEGF receptor-1 […]Read More